5-HT1A Partial Agonist Tandospirone for Behavioral and Psychological Symptoms in Oldest-old Patients with Dementia at a Special Elderly Nursing Home

Prevalence of Comorbid Dementia in Late-life Depression and Bipolar Disorder: A Retrospective Inpatient Study

Background:

Dementia in patients with late-life mood disorders is clinically important.

Objective:

We aimed to investigate the prevalence of dementia in patients with late-life major depressive disorder (MDD) or bipolar disorder (BD) and to clarify the clinical characteristics associated with the diagnosis of dementia.

Methods:

The prevalence of dementia at hospital discharge and the clinical characteristics at hospitalization who are diagnosed with MDD or BD over 65 years of age, from the medical records of 684 patients who had been admitted from 2015 to 2020 were investigated.

Results:

A total of 66 patients with MDD (n = 50) and BD (n = 16) were analyzed. The prevalence of dementia was significantly higher in MDD than in BD (24.0% versus 0%; p = 0.026). The mean age at onset of MDD was significantly older in the MDD with dementia group than in the MDD without (76.9±6.3 years versus 62.2±14.0 years; p < 0.001). The rate of first depressive episode at this admission was significantly higher in the MDD with dementia group (91.7% versus 30.3%; p < 0.001). The diagnosis of dementia was significantly associated with lower scores for “insomnia early” (p = 0.019) and higher scores for “insight” (p = 0.049) on the 17-item Hamilton Depression Rating (HAMD-17) subscales and lower scores for “recall” (p = 0.003) on the MMSE subscales.

Conclusion:

The older age of first onset of depression, “insomnia early”, “insight” and “recall” may be useful indicators for a diagnosis of dementia in late-life depression.

Clinical Analysis on the Effects of Tandospirone Citrate Assisted by Drawing Therapy on Medication Compliance and Sleep Quality in Patients with Anxiety Disorders

Objective

To explore the clinical effects of tandospirone citrate assisted by drawing therapy (DT) on medication compliance and sleep quality in patients with anxiety disorders.

Methods

A total of 128 patients with anxiety disorders treated in the hospital were enrolled between January 2020 and January 2022. According to the random number table method, they were divided into the observation group (n = 64) and the control group (n = 64). The control group was treated with tandospirone citrate, while the observation group was additionally treated with DT. The clinical curative effect and medication compliance after treatment, scores of Hamilton Anxiety Scale (HAMA), Pittsburgh Sleep Quality Index (PSQI), and the World Health Organization's Quality of Life Questionnaire-Brief Version (WHOQOL-BREF) before and after treatment were compared between the two groups. The occurrence of adverse reactions during treatment was recorded.

Results

After treatment, the total response rate in the observation group was higher than that in the control group (96.88% vs 86.94%) (P < 0.05). After treatment, scores of HAMA and PSQI in both groups were decreased, which were lower in the observation group than in the control group (P < 0.05). After treatment, medication compliance in the observation group was higher than that in the control group (P < 0.05). After treatment, scores of environmental factors, social relations, physiological function, and psychological status in both groups were increased, which were higher in the observation group than in the control group (P < 0.05). During treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05).

Conclusion

DT-assisted tandospirone citrate can effectively improve the clinical symptoms of patients with anxiety disorders, improve medication compliance, sleep quality, and quality of life, and have a certain degree of safety.